DGIdb - ANASTROZOLE Drug Record

ANASTROZOLE chembl:CHEMBL1399 ApprovedAntineoplastic

Alternate Names:

ANASTROZOLE
ARIMIDEX
NASTROSA
ICI-D1033
ZD-1033
ANASTROZOL
ALPHA,ALPHA,ALPHA',ALPHA'-TETRAMETHYL-5-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-M-BENZENEDIACETONITRILE
ARIMIDEX®
ZD1033
drugbank:01217
rxcui:84857
chemidplus:120511-73-1
chembl:CHEMBL1399
pubchem.compound:2187

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent
Year of Approval	1995
Drug Class	antineoplastic agents

(6 More Sources)

Publications:

Mauras et al., 2009, Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia., J. Clin. Endocrinol. Metab.
Gangadhara et al., 2009, Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women., Ther Clin Risk Manag
Nabholtz, 2006, Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention., Oncology
Milani et al., 2009, Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women., Clin Med Ther
Santen et al., 2009, History of aromatase: saga of an important biological mediator and therapeutic target., Endocr. Rev.
Cuzick, 2005, Anastrozole., Drugs Today
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Rugo, 2008, The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors., Ann. Oncol.
Jakesz et al., 2007, Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a., J. Natl. Cancer Inst.
Wang L et al., 2010, Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors., Cancer Res
Powlin et al., 1998, Ex vivo and in vitro testis and ovary explants: utility for identifying steroid biosynthesis inhibitors and comparison to a Tier I screening battery., Toxicol. Sci.
O'Connor et al., 1998, An ongoing validation of a Tier I screening battery for detecting endocrine-active compounds (EACs)., Toxicol. Sci.
Miller WR, 2003, Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer., Semin Oncol
Kelly CM et al., 2010, Anastrozole., Expert Opin Drug Saf
Buzdar AU et al., 2002, An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane., Cancer
Rahman et al., 2008, CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma., Drug Metab. Dispos.
Ferrari et al., 2002, Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients., J. Steroid Biochem. Mol. Biol.
Edavana VK et al., 2013, Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics., Drug Metab Dispos
Liu M et al., 2014, Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics., Mol Endocrinol
Gala K et al., 2018, KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function., Oncogene

ANASTROZOLE KMT2C

Interaction Score: 3.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29755131

Sources:
CIViC
ANASTROZOLE CYP19A1

Interaction Score: 2.94

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cytochrome P450 19A1 inhibitor

Direct Interaction yes

Trial Name anastrozole,Arimidex

PMIDs:
19470631 19753124 16439860 19794821 19389994 16034487 11752352 17693420 18073378 20048079 9928669 9928668 14513432 20923259 12404296

Sources:
TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB TTD
ANASTROZOLE TNFSF11

Interaction Score: 1.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ANASTROZOLE TNFRSF11B

Interaction Score: 0.95

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ANASTROZOLE UGT1A4

Interaction Score: 0.68

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23371966

Sources:
PharmGKB
ANASTROZOLE IGF2

Interaction Score: 0.68

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11983488

Sources:
NCI
ANASTROZOLE CYP1B1

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18256205

Sources:
NCI
ANASTROZOLE PGR

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers PharmGKB FDA
ANASTROZOLE TUBB1

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25148458

Sources:
PharmGKB
ANASTROZOLE MAP4K4

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ANASTROZOLE ESR2

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ANASTROZOLE ESR1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers PharmGKB FDA
ANASTROZOLE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB

TEND: ANASTROZOLE
- Version: 01-August-2011
Alternate Names:

ANASTROZOLE Primary Drug Name

Drug Info:

Drug Class antineoplastic agents

Year of Approval 1995

Publications:
TdgClinicalTrial: ANASTROZOLE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: ANASTROZOLE

Version: 14-September-2017

Alternate Names:

C1607 NCI drug code

Drug Info:

Publications:

Ferrari et al., 2002, Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients., J. Steroid Biochem. Mol. Biol.

Rahman et al., 2008, CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma., Drug Metab. Dispos.

Powlin et al., 1998, Ex vivo and in vitro testis and ovary explants: utility for identifying steroid biosynthesis inhibitors and comparison to a Tier I screening battery., Toxicol. Sci.

PharmGKB: anastrozole

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Wang L et al., 2010, Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors., Cancer Res

Edavana VK et al., 2013, Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics., Drug Metab Dispos

Liu M et al., 2014, Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics., Mol Endocrinol

CIViC: ANASTROZOLE
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

Gala K et al., 2018, KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function., Oncogene
TTD: Anastrozole
- Version: 2020.06.01
Alternate Names:

D0W0BF TTD Drug ID

Drug Info:

Publications:
ChemblInteractions: CHEMBL1399
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1399
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: ANASTROZOLE
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:
FDA: Anastrozole
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	Cytochrome P450 19A1 inhibitor
Direct Interaction	yes
Trial Name	anastrozole,Arimidex

ANASTROZOLE Drug Record

ANASTROZOLE chembl:CHEMBL1399 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29755131

Sources: CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Cytochrome P450 19A1 inhibitor Direct Interaction yes Trial Name anastrozole,Arimidex

PMIDs: 19470631 19753124 16439860 19794821 19389994 16034487 11752352 17693420 18073378 20048079 9928669 9928668 14513432 20923259 12404296

Sources: TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23371966

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11983488

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18256205

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationBiomarkers PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25148458

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationBiomarkers PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

TEND: ANASTROZOLE

Alternate Names: ANASTROZOLE Primary Drug Name

Drug Info: Drug Class antineoplastic agents Year of Approval 1995

Publications:

TdgClinicalTrial: ANASTROZOLE

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small Molecule FDA Approval approved

Publications:

NCI: ANASTROZOLE

Alternate Names: C1607 NCI drug code

Drug Info:

PharmGKB: anastrozole

Alternate Names:

Drug Info:

CIViC: ANASTROZOLE

Alternate Names:

Drug Info:

Publications: Gala K et al., 2018, KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function., Oncogene

TTD: Anastrozole

Alternate Names: D0W0BF TTD Drug ID

Drug Info:

Publications:

ChemblInteractions: CHEMBL1399

Interaction Types & Directionality:

n/a

PMIDs:
29755131

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cytochrome P450 19A1 inhibitor

Direct Interaction yes

Trial Name anastrozole,Arimidex

PMIDs:
19470631 19753124 16439860 19794821 19389994 16034487 11752352 17693420 18073378 20048079 9928669 9928668 14513432 20923259 12404296

Sources:
TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23371966

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11983488

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
18256205

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
25148458

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Alternate Names:

ANASTROZOLE Primary Drug Name

Drug Info:

Drug Class antineoplastic agents

Year of Approval 1995

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

C1607 NCI drug code

Publications:

Gala K et al., 2018, KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function., Oncogene

Alternate Names:

D0W0BF TTD Drug ID